March 17, 2020 09:25 AM EDT
R&D

Safe­ty is­sues force No­vo Nordisk to shut­ter PhI­II he­mo­phil­ia tri­als

John Carroll

Editor & Founder

Five months af­ter rolling out proof-of-con­cept da­ta on their an­ti-tis­sue fac­tor path­way in­hibitor con­cizum­ab, No­vo Nordisk abrupt­ly shut down a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times